This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical countermeasures. This contract is not set aside and builds upon HDT Bio Corp's prior work as a prime contractor on federal contracts for rapid response vaccine development, a broad-spectrum RNA antibody platform, and an RNA vaccine for SARS-CoV-2. HDT Bio Corp has also served as a subcontractor supporting research initiatives related to emerging infectious diseases and has received grants from NIH, CDC, DoD, and other agencies for a range of product development efforts.
Generated 3/22/24, 6:53 PM